• Chemical Composition

    Etamsylate 500 mg / 1 tab

  • Packing


  • Medical Id


  • License Number


  • License date


Mechanism Of Action Etamsylate is a synthetic antihaemorrhagic and angioprotective drug acting on the first step of haemostasis (endothelium –platelet interaction ). By improving Platelet adhesiveness and restoring capillary resistance, it is able to reduce bleeding time and blood losses. Etamsylate has no vasoconstrictor action, it does not influence fibrinolysis nor modify the plasma coagulation factors.
INDICATIONS In Surgery: Prevention and treatment of pre, per or postsurgical capillary haemorrhages in all delicate operations and in those affecting highly vascularised tissues: E.N.T., gynaecology, obstetrics, urology, odontostomatology, ophthalmology, plastic and reconstructive surgery. In internal medicine: Prevention and treatment of capillary haemorrhages of whatever origin or localization: haematuria, haematemesis, melaena, epistaxis, gingivorrhagia. In gynaecology: Metrorrhagia, primary or IUD-related menorrhagia in the absence of organic pathology.
Side EFFECTS Rare: gastralgia, nausea, headache, skin rash. In most cases these symptoms disappear spontaneous. If they persist, the dosage should be reduced or the treatment withdrawn.
WARNINGS Parenteral administration of etamsylate may induce a drop in blood pressure, but no data have been reported on such risk during oral administration. If HEM-SAT 500 is administered for a reduction of excessive and/or prolonged menstrual haemorrhages, and no improvement is observed, possible pathological causes should be looked for and excluded.
Pregnancy And lactations Pregnancy category C: studies in pregnant women or animals are not available. As a precaution, HEM-SAT 500 should not be administered during the first trimester of pregnancy, whereas the second and third trimesters, it should be administered only if expected therapeutic benefit is judged as superior to the potential risk for the foetus. In the absence of date regarding passage into maternal milk, lactation during treatment is not advisable or, if lactation is to continue, the treatment must be stopped.
Dosage And Administration Adults: Pre surgical: 1 tablet (500mg) 1 hour before surgery. Postsurgical: 1 tablet (500mg) every 4-6 hours as long as the risk of bleeding persists. Internal medicine: Generally 1 tablet (500 mg) 2-3 times a day. (1000-1500 mg) not to be taken with meal with a little water, treatment duration depends on results obtained. Gynaecology, meno-metrorrhagia: 1 tablet (500 mg) 3 times a day (1500 mg) to be taken with meals with a little water. Treatment lasts 10 days and starts 5 days before the expected onset of menses. Children: Half the adult dose of 250 mg tablet. Because of its high concentration of active principle, HEM-SAT 500 is not appropriate for children.
Storage Conditions Keep out of reach of children Store in a cool dry place (20° – 25°C)